Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: marc ultra who wrote (1829)	3/19/1998 5:04:00 PM
From: Joe Wesley	Respond to of 4676

Hi Mark: From the lack of information given out by Isis with respect to 2302 and the length of these other P2's compared to the Crohn's trial many (at least within my investment group) were beginning to question 2302. Now from the 10-K405 just filed 2302 (and a second generation drug) will continue in psoriasis as a topical formulation. They give status on the other trials and mention they are exploring local delivery to the lungs for asthma. Bottom line Isis and BI are still excited about ICAM-1 antisense. Another tidbit was 5132 is going forward in combination with current chemotherapeutic agents. Amateur